Pancreatic cancer: understanding and overcoming chemoresistance

被引：274

作者：

Wang, Zhiwei ^{[1
]}

Li, Yiwei ^{[1
]}

Ahmad, Aamir ^{[1
]}

Banerjee, Sanjeev ^{[1
]}

Azmi, Asfar S. ^{[1
]}

Kong, Dejuan ^{[1
]}

Sarkar, Fazlul H. ^{[1
]}

机构：

[1] Wayne State Univ, Dept Pathol, Karmanos Canc Inst, Sch Med,Hudson Webber Canc Res Ctr 740, Detroit, MI 48201 USA

来源：

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY | 2011年 / 8卷 / 01期

关键词：

EPITHELIAL-MESENCHYMAL TRANSITION; DRUG-RESISTANCE; SIDE POPULATION; CELL-LINES; STEM-CELLS; GEMCITABINE; MICRORNAS; SENSITIVITY; EXPRESSION; INVASION;

D O I：

10.1038/nrgastro.2010.188

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Pancreatic cancer is a highly aggressive malignancy. This feature is believed to be partly attributable to the chemotherapy-resistant characteristics of specific subgroups of pancreatic cancer cells, namely those with an epithelial-mesenchymal transition (EMT) phenotype and cancer stem cells. Accumulating evidence suggests that several new and emerging concepts might be important in the drug-resistant phenotype of these cell types. An understanding of the molecular mechanisms underlying drug resistance in patients with pancreatic cancer might help researchers to devise novel strategies to overcome such resistance. In particular, microRNAs (miRNAs) seem to be critical regulators of drug resistance in pancreatic cancer cells. Selective and targeted elimination of cells with an EMT phenotype and cancer stem cells could be achieved by regulating the expression of specific miRNAs.

引用

页码：27 / 33

页数：7

共 59 条

[1] RETRACTED: Gemcitabine Sensitivity Can Be Induced in Pancreatic Cancer Cells through Modulation of miR-200 and miR-21 Expression by Curcumin or Its Analogue CDF (Retracted article. See vol. 78, pg. 5466, 2018)
Ali, Shadan
Ahmad, Aamir
Banerjee, Sanjeev
Padhye, Subhash
Dominiak, Kristin
Schaffert, Jacqueline M.
Wang, Zhiwei
Philip, Philip A.
Sarkar, Fazlul H.
[J]. CANCER RESEARCH, 2010, 70 (09) : 3606 - 3617
[2] Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer
Arumugam, Thiruvengadam
Ramachandran, Vijaya
Fournier, Keith F.
Wang, Huamin
Marquis, Lauren
Abbruzzese, James L.
Gallick, Gary E.
Logsdon, Craig D.
McConkey, David J.
Choi, Woonyoung
[J]. CANCER RESEARCH, 2009, 69 (14) : 5820 - 5828
[3] INNOVATION Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications
Brown, Brian D.
Naldini, Luigi
[J]. NATURE REVIEWS GENETICS, 2009, 10 (08) : 578 - 585
[4] Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition
Buck, Elizabeth
Eyzaguirre, Alexandra
Barr, Sharon
Thompson, Stuart
Sennello, Regina
Young, David
Iwata, Kenneth K.
Gibson, Neil W.
Cagnoni, Pablo
Haley, John D.
[J]. MOLECULAR CANCER THERAPEUTICS, 2007, 6 (02) : 532 - 541
[5] Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126
[6] Integrins as Novel Drug Targets for Overcoming Innate Drug Resistance
Damiano, Jason S.
[J]. CURRENT CANCER DRUG TARGETS, 2002, 2 (01) : 37 - 43
[7] Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma
Dembinski, Jennifer L.
Krauss, Stefan
[J]. CLINICAL & EXPERIMENTAL METASTASIS, 2009, 26 (07) : 611 - 623
[8] Pancreatic Cancer Cells Resistant to Chemoradiotherapy Rich in "Stem-Cell-Like" Tumor Cells
Du, Zhiyong
Qin, Renyi
Wei, Cuifeng
Wang, Min
Shi, Chengjian
Tian, Rui
Peng, Chenghong
[J]. DIGESTIVE DISEASES AND SCIENCES, 2011, 56 (03) : 741 - 750
[9] The therapeutic promise of the cancer stem cell concept
Frank, Natasha Y.
Schatton, Tobias
Frank, Markus H.
[J]. JOURNAL OF CLINICAL INVESTIGATION, 2010, 120 (01) : 41 - 50
[10] Targeting microRNAs in cancer: rationale, strategies and challenges
Garzon, Ramiro
Marcucci, Guido
Croce, Carlo M.
[J]. NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (10) : 775 - 789

← 1 2 3 4 5 6 →